Life Sciences and Healthcare

What Europe’s MDR means for manufacturers of legacy devices

Clarivate regulatory expert  Mónica Colina reviews key aspects of the European Commission’s Medical Device Regulation (MDR) to be considered for surveillance audits of medical devices certified under the repealed directives.  The European Commission’s Medical Device Regulation rules, first published in May 2017, became applicable in all European member states in May of this year. The […]

Healthcare Business Insights 2021 Virtual Summit: Top four themes for hospital executives

Clarivate Executive Director Jerica Hopkins distills the top themes and takeaways from the Healthcare Business Insights 2021 Virtual Summit, where hospital executives gather to learn, share best practices and network about industry challenges and opportunities. This past month, Clarivate hosted its 2021 Healthcare Business Insights Virtual Summit, Converting crises into a new era of modus […]

Impact of COVID-19 on patient volumes, procedure utilization and site of service

The COVID-19 pandemic has had a negative impact on healthcare patient volumes, procedure utilization and sites of service, and the effect has varied by procedure urgency. In this article, Clarivate analysts detail which procedures and sites fared the best and which are most likely to recover as more of the population is vaccinated, a critical […]

Volume-Based Procurement in Mainland China: Key trends and planning future strategies

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate expert Karan Verma discusses how the Volume-Based Procurement program is transforming the generics landscape, increasing patient access and prompting manufactures to rethink strategies.   Remodeling Mainland […]

Paradigm-changing primary Phase III data for malignant melanoma: What to expect from Relatlimab in combination with Opdivo

Bristol’s Relatlimab/Opdivo (anti-LAG-3/PD-1) therapy is poised to make inroads into its own Opdivo/Yervoy (PD-1/CTLA-4) inhibitor combination share for malignant melanoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Liseth Parra and Rachel Webster review new data shared at ASCO 2021, and implications for patients and life sciences companies.   Compelling Phase III […]

How will COVID-19 vaccine rollout differ by country?

COVID-19 vaccination represents a critical component in the recovery of medtech markets for healthcare capacity, patient mobility and the full restoration of global manufacturing operations and supply chains. To understand the effect of various vaccination campaigns, we need to understand the rollout by region and country. Clarivate experts developed a vaccination forecast model to illustrate […]

KEYNOTE-564 paves future role for immunotherapy in adjuvant renal cell carcinoma

Merck &Co.’s Keytruda has practice-changing potential as adjuvant therapy for renal cell carcinoma. As part of our Drugs to Watch™ series, Clarivate oncology experts Priyanka Mehra and Sorcha Cassidy review new data shared at the 2021 ASCO Annual Meeting, and implications for patients and life sciences companies.   The renal cell carcinoma treatment landscape continues […]

The evolution of the asset-centric approach in biotech venture capital

In this episode of Conversations in Healthcare, Mike Ward speaks with Francesco De Rubertis, co-founder and managing partner at Medicxi, about the evolution of the biotech venture capital model and the emergence of the asset-centric approach.   Mike Ward: I’m delighted to be joined by Francesco De Rubertis, a co-founder and managing partner at Medicxi, […]

Roche’s Tecentriq shows promise in resectable NSCLC: key takeaways for the market

Tecentriq, Roche’s flagship anti-PD-L1 therapy, gets one step closer to becoming the first immunotherapy to gain approval as adjuvant therapy in resectable non-small cell lung cancer (NSCLC). As part of our Drugs to Watch™ series, Clarivate oncology experts Arman Esfandiari, Amardeep Singh and Khurram Nawaz review new data shared at ASCO 2021, and implications for […]